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CCL27 chemokine in early mycosis fungoides
Goteri et al. investigated the clinical and prognostic signifi-
cance of the cutaneous T-cell attracting chemokine, CTACK/
CCL27, in early-stage mycosis fungoides (MF). Samples 
were taken from 15 patients at the time of diagnosis and 
after the end of treatment with psoralen plus ultraviolet A/
interferon alfa-2b combination therapy. Eight patients expe-
rienced a relapse: the combination of high CTACK/CCL27 
levels in both sera and skin increased the probability of 
experiencing an event at 51 months from 36% to 83%. It is 
concluded that CTACK/CCL27 levels in skin and sera after 
therapy might be correlated with risk of recurrence. The res-
toration of normal cutaneous and serum CTACK/CCL27 lev-
els in early MF might be a useful endpoint in the treatment 
of this disease. Br J Dermatol 2012; 166: 948–52.
P-cadherin expression in Merkel  
cell carcinomas
Vlahova et al. examined the prevalence and prognostic rel-
evance of E-, N- and P-cadherin in Merkel cell carcinoma 
(MCC). MCC samples (n = 148) from 106 different patients 
were analysed. Ninety-one per cent of all MCC were positive 
for N-cadherin whereas only 61.6% and 70.3% expressed 
E- and P-cadherin, respectively. Merkel cell polyomavirus 
DNA was detected in 78.2% of all MCC, more frequently 
in P-cadherin- positive MCC (P = 0.0008). P-cadherin was 
significantly more frequent in primary tumours than in 
lymph node metastases (81.9% vs. 40.9%, P = 0.0002). 
Patients with P-cadherin-positive primary tumours were in 
earlier tumour stages at initial diagnosis (P = 0.0046) and 
had significantly prolonged recurrence-free survival (median 
9.0 vs. 4.0 months). By contrast, patients with E-cadherin-
positive MCCs had a trend for decreased recurrence-free 
survival. This protein may constitute a valuable tool for 
identifying patients who benefit from close follow-up. Br J 
Dermatol 2012; 166: 1043–52.
Association of AHR polymorphisms  
and vitiligo risk
Wang et al. genotyped two single nucleotide polymor-
phisms of the aryl hydrocarbon receptor (AHR) gene, 
rs10249788 and rs2066853, in an ongoing, hospital-
based, case–control study of vitiligo in Han Chinese popu-
lations. A statistically significantly decreased risk of vitiligo 
was found to be associated with the TT and CT genotypes 
of rs10249788 as well as among subgroups: male, active, 
nonsegmental vitiligo, and onset age ≤ 20 years. Moreover, 
subjects with the combined (CT + TT)/GG genotype or T/G 
haplotype (rs10249788/rs2066853) showed a decreased 
risk for vitiligo. These results suggest that functional poly-
morphisms of the AHR gene may affect the susceptibility 
and clinical progression of vitiligo in Han Chinese popula-
tions. Br J Dermatol 2012; 166: 1081–87.
COX-2 inhibition restores UVB-induced 
downregulation of ATP2A2/SERCA2
ATP2A2 gene encoding the sarcoplasmic/endoplasmic retic-
ulum Ca2+-ATPase2 (SERCA2) is a responsible gene in Darier 
disease (DD). Kamijo et al. report that cyclooxygenase-2 
(COX-2) knockdown by siRNA resulted in upregulation of 
ATP2A2 transcription. Treatment by celecoxib rescued ultra-
violet (UV) B-mediated suppression of ATP2A2 transcription 
and SERCA2 protein expression. Addition of prostaglandin 
(PG) E2, a product of COX-2 enzyme, reduced the amounts 
of ATP2A2 mRNA and SERCA2 protein in keratinocytes. 
It is concluded that UVB downregulates ATP2A2/SERCA2 
expression via induction of COX-2 expression and subse-
quent increase of PGE2 production in keratinocytes. This find-
ing suggests a possible therapeutic approach with selective 
COX-2 inhibition for patients with DD. Br J Dermatol 2012; 
166: 1017–22.
